Leal Sheds Light on Symptoms and Treatment of Lambert-Eaton Myasthenic Syndrome
September 15th 2022Dr Leal discusses the symptoms commonly associated with Lambert-Eaton Myasthenic Syndrome, the prevalence of this disorder in concurrence with underlying cancers, and how amifampridine can help manage this disease by improving motor and autonomic symptoms.
Read More
Chen Discusses Diagnosis, Management, and Disparities in Cutaneous T-cell Lymphoma
September 8th 2022Dr Chen details the findings from a study of patients with transformed cutaneous T-cell lymphoma, gives her perspective on findings from the FLASH trial, and discusses the need for more research funding in this disease.
Read More
FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Low Unresectable or Metastatic Breast Cancer
September 5th 2022Dr Modi discusses the significance of the FDA approval of trastuzumab deruxtecan in metastatic HER2-low breast cancer, pivotal efficacy and safety data from the DESTINY-Breast04 trial, and how these findings pave the way for further progress across cancer therapy.
Read More
Drs Bekaii-Saab, George, and von Mehren discuss patient-reported outcomes from the INTRIGUE trial, the rationale for a phase 1/2 study investigating DCC-3116 in patients with RAS or RAF–mutated solid tumors, and how vimseltinib may alleviate unmet needs in the tenosynovial giant cell tumors population.
Read More
FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Mutant NSCLC
August 25th 2022Dr Levy discusses the significance of the FDA approval of trastuzumab deruxtecan in HER2-mutant NSCLC, the pivotal efficacy and safety data from the DESTINY-Lung02 trial, and the optimal use of companion diagnostic tests in the field.
Read More
Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer
August 22nd 2022Dr Petrylak discusses current issues with genetic testing and disease management in prostate and bladder cancer, some of the reasons for poor testing rates, and the importance of proper multidisciplinary management during testing and when seeking to mitigate adverse effects.
Read More
Goldberg and Sussman Dissect Disparities in Gastric Cancer Mortality Rates
August 18th 2022Drs Goldberg and Sussman discuss key findings from their research on rates of gastrointestinal mortality, the factors that could contribute to these differences, and ways these disparities can be addressed.
Read More
FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
August 15th 2022Dr Berchuck discusses the effects of treatment intensification with darolutamide in metastatic hormone-sensitive prostate cancer, the significance of the approval of darolutamide plus docetaxel and androgen deprivation therapy, and questions left unanswered by the pivotal ARASENS study.
Read More
Katz Considers the Role of Neoadjuvant Chemoradiation in Borderline Resectable Pancreatic Cancer
August 11th 2022Dr Katz discusses the implications of a recently published phase 2 study investigating neoadjuvant mFOLFIRINOX with or without hypofractionated radiation therapy results for patients with borderline resectable pancreatic ductal adenocarcinoma.
Read More
Leukemia Experts Reflect on Defining Moments as Women in the Field
August 8th 2022Drs Luger, Roboz, and Stock discuss the issues that were most prominent in leukemia treatment when they began their careers and what motivated them to continue to work toward progress in the field even when treatment outcomes were dismal. They also share their experiences with being women in their chosen career paths, such as how their gender has influenced their professional and personal decisions, as well as how they interact with and support other female colleagues.
Read More
Gradishar Stresses the Importance of Accurately Defining Breast Cancer Subtypes
August 4th 2022Dr Gradishar emphasizes the importance of defining metastatic breast cancer subtypes, the implications of molecular testing on treatment decisions, and the need for comprehensive patient-provider communication about therapeutic options and clinical trial opportunities throughout the course of disease.
Read More
Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology
August 1st 2022Dr Subbiah discusses research from the 2022 ASCO Annual Meeting, including phase 2 data (NCT04165772) in mismatch repair–deficient, locally advanced rectal cancer; findings from DESTINY-Breast04 (NCT03734029) in HER2-low unresectable and/or metastatic breast cancer; a first-in-human study (NCT04585750) in TP53-mutant advanced solid tumors; and data from LIBRETTO-001 (NCT03157128) in RET fusion–positive solid tumors.
Read More
FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL
July 28th 2022Dr Ghosh discusses the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma, pivotal efficacy and safety data from the phase 3 TRANSFORM trial (NCT03575351) and the phase 2 TRANSCEND-PILOT-017006 study (NCT03483103), and the effect of the approval on academic and community center practice patterns.
Read More
P53-Mutated MCL Remains Difficult to Treat
July 22nd 2022Mutations in the p53 gene are associated with poor prognosis for patients with mantle cell lymphoma. Although modern regimens have improved outcomes, those treatments are associated with significant toxicity and, so far, have produced limited efficacy.
Read More
An influx of bispecific T-cell engagers, CAR T-cell therapies, and antibody-drug conjugates have revolutionized the treatment of hematologic malignancies; however, with several options in the sandbox, accessibility and unexplored clinical questions present challenges for optimal integration of these options into treatment.
Read More
ASCT No Longer Suitable for the Majority of Patients with DLBCL
July 22nd 2022Most patients with diffuse large B-cell lymphoma do not derive significant benefit from treatment with autologous stem cell transplantation and better therapeutic options are currently available for this population.
Read More
Westin and Sehn Carve Out the Role of CAR T-Cell Therapy and Transplant in Primary Refractory DLBCL
July 21st 2022CAR T-cell therapy, autologous stem cell transplant, and novel agents each have a role to play in the second-line management of patients with primary refractory diffuse large B-cell lymphoma, according to Jason Westin, MD, MS, FACP, and Laurie H. Sehn, MD, MPH.
Read More
Pooled Real-World Data Support Earlier Line Use of IRd in Relapsed/Refractory Multiple Myeloma
July 21st 2022A pooled analysis of the INSIGHT MM, UVEA-IXA, and REMIX observational studies found that real-world outcomes with ixazomib/lenalidomide/dexamethasone were consistent with those reported in the TOURMAILINE-MM1 study.
Read More
Mosunetuzumab Monotherapy Generates Promising Responses in Relapsed/Refractory Follicular Lymphoma
July 20th 2022Single-agent mosunetuzumab produced a complete response rate that was greater than what has been observed with historical controls in patients with relapsed/refractory follicular lymphoma who had received at least 2 prior lines of therapy, meeting the primary end point of the expansion portion of the phase 1/2 GO29781 trial.
Read More
Zanubrutinib was found to significantly improve progression-free survival over a doublet comprised of bendamustine plus rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from cohort 1 of the phase 3 SEQUOIA trial.
Read More
CB-010 Exhibits Impressive Early Efficacy in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
July 20th 2022The CAR T-cell therapy CB-010 displayed promising preliminary efficacy and safety results in patients with relapsed/refractory B-cell non-Hodgkin lymphoma according to findings from the phase 1 ANTLER trial presented during the 2022 Pan Pacific Lymphoma Meeting.
Read More